GENEVA—Reviews of CD8-positive T-cell infiltration as an independent prognostic biomarker in resected non-small cell lung cancer, and the potential of checkpoint inhibitor therapy for mesothelioma after first or second line chemotherapy were presented at the European Lung Cancer Conference by Martin Reck MD PhD, from the Lung Clinic Grosshansdorf in Germany. He discussed the clinical implications with Oncology Times reporter Peter Goodwin.
You may also like...
Combined Intracavitary/Interstitial Brachytherapy: New benchmark for Cervical Cancer 5 May, 2015 No Prime Time Soon for Vaccines in Lung Cancer—Immune Suppression Reversal Urgently Needed 20 Apr, 2015 Which Tasks Most Influence Pediatric PT Productivity, Effectiveness? 31 Dec, 2019 World Malaria Day Report from Africa and London: Chris Drakeley, LSHTM 24 Apr, 2012
- Previous story Prior Chemotherapy: No Bar to Checkpoint Inhibition in Mesothelioma
- Next story New Drug for Patients with EGFR-TKI-resistant Advanced Non-Small Cell Lung Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014